Please use this identifier to cite or link to this item: https://scholarbank.nus.edu.sg/handle/10635/214519
Title: DRUG REPURPOSING FOR MYCOBACTERIUM ABSCESSUS: INVESTIGATING DRUG COMBINATIONS
Authors: DINAH BINTE AZIZ
ORCID iD:   orcid.org/0000-0001-6223-1654
Keywords: mycobacterium abscessus, drug repurposing, synergy, erm41, whiB7, rifabutin
Issue Date: 20-Aug-2021
Citation: DINAH BINTE AZIZ (2021-08-20). DRUG REPURPOSING FOR MYCOBACTERIUM ABSCESSUS: INVESTIGATING DRUG COMBINATIONS. ScholarBank@NUS Repository.
Abstract: Lung disease caused by Mycobacterium abscessus is difficult to cure due to drug resistance. With an increasing number of cases reported worldwide, there is an urgent medical need for more effective therapeutic options. Drug repurposing, the identification of drugs in use for other disease indications, is an attractive strategy to identify novel candidates for the treatment of M. abscessus infections. The overarching goal of this study is to identify novel combinations of approved drugs with synergistic or potentiating activities. To date, we confirmed rifabutin – clarithromycin synergy. Its mechanism is based on the suppression of transcription of the clarithromycin resistance gene erm41. Furthermore, we identified teicoplanin-tigecycline, and vaborbactam-tebipenem as several other novel synergistic drug combinations. In conclusion, this work identified a series of novel drug combinations showing synergy against M. abscessus in vitro and thus provides the basis for testing these novel treatment options in animal models and in clinical trials.
URI: https://scholarbank.nus.edu.sg/handle/10635/214519
Appears in Collections:Ph.D Theses (Open)

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
AzizD.pdf1.72 MBAdobe PDF

OPEN

NoneView/Download

Page view(s)

50
checked on Sep 29, 2022

Download(s)

8
checked on Sep 29, 2022

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.